SciELO - Scientific Electronic Library Online

 
vol.17 issue4The Boston Naming Test as a predictor of post-surgical naming dysfunctions in temporal lobe epilepsyEffectiveness of the use of an omega 3 and omega 6 combination(EquazenTM) in paediatric patients with refractory epilepsy author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Journal of Epilepsy and Clinical Neurophysiology

Print version ISSN 1676-2649

Abstract

THOME-SOUZA, Sigride  and  VALENTE, Kette D. R.. Orphan drug: arisement of new concept. J. epilepsy clin. neurophysiol. [online]. 2011, vol.17, n.4, pp. 144-147. ISSN 1676-2649.  http://dx.doi.org/10.1590/S1676-26492011000400006.

INTRODUCTION: Four new antiepileptic drugs have been approved since 2007, eslicarbazepine acetate, lacosamide, rufinamide and stiripentol. Out of these, two drugs are orphan drugs, that is, drugs specifically designed for the treatment of a specific epileptic syndrome, such as stiripentol for Dravet Syndrome and rufinamide for Lennox-Gastaut Syndrome. OBJECTIVE: to review the efficacy, tolerability and adverse effects of the newly released drugs, especially of both orphan drugs. METHODOLOGY: Studies were selected from electronic data base. Analyses of these studies ascertained the most common, rare and long-term adverse effects, efficacy, and effectiveness, as well as comparison with existing drugs. CONCLUSIONS: The development of specific drugs in the treatment of epileptic syndromes constitutes the cornerstone in the treatment of epilepsy, minimizing the time needed to achieve seizure control, with consequent reduced exposure to the deleterious effects of epilepsy.

Keywords : orphan drug; stiripentol; rufinamide; Dravet Syndrome; Lennox-Gastaut Syndrome.

        · abstract in Portuguese     · text in Portuguese     · pdf in Portuguese